论文部分内容阅读
目的 :探讨胃舒胶囊对萎缩性胃炎癌前病变的治疗作用及机制。方法 :192例萎缩性胃炎癌前病变患者随机分为两组 ,治疗组 (12 8例 )给予胃舒胶囊口服 ,对照组 (6 4例 )给予胃宁冲剂冲服 ,疗程均为 6个月。观察两组患者临床、内镜、病理疗效及治疗前后AgNOR颗粒数、增殖细胞核抗原 (PCNA)表达积分值的变化。 结果 :治疗组临床总有效率为 91 4% ,胃镜有效率 70 3% ,对萎缩、肠上皮化生、异型增生的有效率分别为 6 4 1%、6 6 4%、6 7 9% ,并能降低其积分值。治疗组治疗前后免疫组化结果显示 ,胃舒胶囊也能显著降低AgNOR颗粒数、抑制PCNA的表达 ,与对照组比较差异有显著性意义 (P <0 0 1,<0 0 5 )。结论 :胃舒胶囊对萎缩性胃炎癌前病变的临床症状、胃镜征象、病理变化有显著改善作用 ,其机制可能与抑制和纠正细胞的异常增殖和分化有关。
Objective: To explore the therapeutic effect and mechanism of Weishu Capsule on precancerous lesion of atrophic gastritis. Methods: 192 patients with precancerous lesions of atrophic gastritis were randomly divided into two groups. The treatment group (128 cases) were given Weishu capsules orally, and the control group (64 cases) were given Weining Granules, and the course of treatment was 6 months. The clinical, endoscopic, pathological and therapeutic effects of AgNOR and PCNA expression before and after treatment were observed in both groups. Results: The total effective rate in the treatment group was 91 4%, the gastroscopy efficiency was 70 3%, and the effective rates for atrophy, intestinal metaplasia, and dysplasia were 6 4%, 6 4%, and 6 7 9%, respectively. And can reduce its integral value. The results of immunohistochemistry before and after treatment in the treatment group showed that Weishu Capsule could also significantly reduce the number of AgNOR particles and inhibit the expression of PCNA, which was significantly different from that of the control group (P <0 01, <0 05). Conclusion :Weishu Capsule has significant effect on the clinical symptoms, gastroscopy and pathological changes of precancerous lesions of atrophic gastritis. The mechanism may be related to the inhibition and correction of abnormal proliferation and differentiation of cells.